ARCHIVES

. R.L.; K.D.; Fuchus, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Portwit A, et al. (July 2009).. Blood. 114 (5): 937–951.
3. Stewart B, Wild CP, eds. (2014). World Cancer Report 2014. World Health Organization. pp. Chapter 5.13
4. uo PS (2001). Concise Dictionary of Biomedicine and molecular Biology (2nd ed. ) Hoboken: CRC Press.p. 653.
5. Cancer Rehabilitation Medicine Quick Reference (RMQR). New York: Demos Medical Publishing . 2013. p. 26. ISBN 9781617050008. [6].
6. Gill, S.; June, C.H. Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015, 263, 68–89.
7. Adjei, I.M.; Sharma, B.; Peetla, C.; Labhasetwar, V. Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an
intraosseous model of prostate cancer. J. Control. Release 2016, 232, 83–92.
8. Mathers, Colin D, Cynthia Boschi-Pinto, Alan D Lopez and Christopher JL Murray (2001). Cancer incidence, mortality and survival by site
for 14 regions of the world. Global Programme on Evidence for Health Policy Discussion Paper No. 13 World Health Organization.
9. Leonard, Barry (1998). Leukemia: A Research Report. DIANE Publishing. 7. ISBN 0-7881-7189-5.
10. Ross, J. A., Kasum, C. M., Davies, S. M., Jacobs, D. R., Folsom, A. R., & Potter, J. D. (2002). Diet and risk of leukemia in the Iowa
Women’s Health Study. Cancer Epidemiology and Prevention Biomarkers, 11(8), 777-781.
11. Wiernik, Peter H. (2001). Adult Leukemia (ACS ATLAS OF CLINICAL ONCOLOGY) (American Cancer Society atlas of clinical
oncology). pmph usa. ISBN 13: 9781550091113.
12. Boffetta, P. (2011). I. Epidemiology of adult non-Hodgkin lymphoma. Annals of oncology, 22, iv27-iv31.
13. Boffetta, P. (2011). I. Epidemiology of adult non-Hodgkin lymphoma. Annals of oncology, 22, iv27-iv31.
14. Stass, Sanford A.; Schumacher, Harold R.; Rock, William R. (2000). Handbook of hematologic pathology. New York, 193–194. ISBN 0-
8247-0170-4.
15. DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653.
16. Knoepfler PS (2009) Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem cells 27(5): 1050-1056.
17. Hof PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus
leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol
19(8):2282–2292.
18. Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for
anti-cancer drug delivery. J Control Release 148(2):135–146.
19. Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J
Pharm Biopharm 93(March):52–79.
20. Sbeity H and Younes R (2015) Review of optimization methods for cancer chemotherapy treatment planning. J Comput Sci Syst Biol 8(2):74–
95
21. Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, et al. (2012) Novel targeted system to deliver chemotherapeutic drugs to EphA2-
expressing cancer cells. J Med Chem 55(5): 2427-2436.
22. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, et al. (2004) Tumor progression while onchemotherapy: a contraindication to liver
resection for multiple colorectal metastases?. Ann Surg 240(6): 1052- 1061.
23. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, et al. (1988) Cisplatin plus etoposide consolidation following cyclophosphamide,
doxorubicin, ,and vincristine in limited small-cell lung cancer. J Clin Oncol 6(3): 451-456.
24. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, et al. (1999) Prospective evaluation of paclitaxel versus combination
chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin
Oncol 17(11): 3412-3417.
25. Peters III WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, et al. (2000) Concurrent chemotherapy and pelvic radiation therapy compared with
pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol
18(8): 1606-1613.
26. Fishman PN, Pond GR, Moore MJ, Oza A, Burkes RL, et al. (2006) Natural history and chemotherapy effectiveness for advanced
adenocarcinoma of the small bowel: a retrospective review of 113 cases. American J Clin Oncol 29(3): 225-231.
27. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, et al. (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment
of patients with early-stage breast cancer: an open-label, 2× 2 factorial, randomised phase 3 trial. The Lancet 385(9980): 1863-1872.
28. 24. Feldman BJ, Feldman D (2001) The development of androgen independent prostate cancer. Nat Rev Cancer 1(1): 34-45.
29. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, et al. (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with
unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36):
9243-9249.
30. Brown SB, Brown EA, Walker I (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5(8): 497- 508.
31. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, et al. (2006) Abraxane®, a novel Cremophor®-free, albumin-bound particle
form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17(8): 1263-1268.
32. Spinetta JJ, Jankovic M, Masera G, et al. Optimal care for the child with cancer: A summary statement from the SIOP working committee
on psychosocial issues in pediatric oncology. Pediatr Blood Cancer 2009; 52(7): 904-7.
33. Costa-Silva TA, Costa IM, Biasoto HP, et al. Critical overview of the main features and techniques used for the evaluation of the clinical
applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Rev 2020; 43: 100651.
34. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet NG: Normal tissue reactions to radiotherapy: towards
tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-142.
35. Delaney G, Jacob S, Featherstone C, Barton M: The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of
evidence-based clinical guidelines. Cancer 2005; 104: 1129-1137.
36. Begg AC, Stewart FA, Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11: 239-253
37. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet NG: Normal tissue reactions to radiotherapy: towards
tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-142.
38. Naeem N, Reed MD, Creger RJ, Youngner SJ, Lazarus HM. Transfer of the hematopoietic stem cell transplant patient to the intensive care
unit: Does it really matter? Bone Marrow Transplant 2005; 37: 119-33.
39. Güneş M, Kılıç R, Patıroğlu T, Ezer U, Kürekçi A. Evaluation of transplanted stem cell dynamic variables in the bone marrow of children with
malignancies. J Biomed Allied Res 2023; 5(1): 1-
40. Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European
Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplant 2011;
47: 473-82.
41. Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL. Short- and long-term effects of acute myeloid leukemia on patient
health-related quality of life. Cancer Treat Rev 2004; 30(1): 103- 17.
42. Hayden PJ, Keogh F, Conghaile MN, Carroll M, Crowley M, Fitzsimon N. A single-centre assessment of long-term quality-of-life status after
sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in the first chronic phase. Bone Marrow Transplant 2004; 34(6):
545-56.
43. Halme DG, Kessler DA. FDA regulation of stem-cell–based therapies. Mass Med Soc. 2006;2:254.
44. Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71(6): 907-20.
45. Messerschmidt JL, Prendergast GC, Messerschmidt GL. How cancers escape immune destruction and mechanisms of action for the new
significantly active immune therapies: Helping non immunologists decipher recent advances. Oncologist 2016; 21(2): 233- 43
46. Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Karagiannidis A. Invasive fungal diseases in children with hematological
malignancies treated with therapies that target cell surface antigens: Monoclonal antibodies, immune checkpoint inhibitors and CAR T Cell
therapies. J Fungi 2021; 7(3): 186.
47. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: Immunomodulation, CARs and combination
immunotherapy. Nat Rev Clin Oncol 2016; 13(5): 273-90.
48. Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current progress in CAR-T cell therapy for hematological malignancies. J Cancer 2021; 12(2): 326.
49. Riley RS, Day ES. Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley
Interdiscip Rev Nanomed Nanobiotechnol 2017; 9(4): e1449.
50. McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with
targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis. Lancet Oncol 2018; 19(3): 310-22.
http://dx.doi.org/10.1016/S1470-2045(18)30078-0 PMID: 29449192.
51. Gao Z, Huang S, Wang S, Tang D, Xu W, Zeng R. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted
therapy as first-line treatment for advanced and metastatic esophageal cancer: A systematic review and network metaanalysis. Lancet Reg
Health West Pac 2023; 38: 100841.
52. Boons E, Nogueira TC, Dierckx T, et al. XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering
p53-mediated caspase-dependent apoptosis. Blood Cancer J 2021; 11(2): 27.
53. Madeddu C, Gramignano G, Astara G, et al. Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted
mechanism-based approach. Front Physiol 2018; 9(SEP): 1294.
54. Glimelius B, Garmo H, Berglund Å, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal
cancer. Pharmacogenomics J 2011; 11(1): 61-71.